TD Asset Management
AMLX icon

TD Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

TD Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,966
Closed -$557K – 1238
2025
Q3 		$557K Buy
+40,966
New +$386K ﹤0.01% 1165
2024
Q2 		– Sell
-131,200
Closed -$373K – 1365
2024
Q1 		$373K Buy
131,200
+16,200
+14% +$212K ﹤0.01% 1324
2023
Q4 		$1.69M Buy
+115,000
New +$1.76M ﹤0.01% 1061

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

TD Asset Management's AMLX Position: Q4 2025 in Review

TD Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 40,966 shares — an estimated $557K sold.

TD Asset Management first reported a position in AMLX in Q4 2023 and held it in 3 quarters. The position peaked at $1.69M in Q4 2023. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • TD Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • TD Asset Management sold 40,966 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $557K.
  • TD Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • TD Asset Management's Amylyx Pharmaceuticals position peaked at $1.69M in Q4 2023.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on TD Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.